

Diabetes Meds for Type 2: **Objectives**




- 1. Describe the main action of the different categories of type 2 diabetes medications.
- 2. Discuss strategies to determine the right medication for the right patient.
- 3. List the side effects and clinical considerations of each category of medication.



Poll question 1

- ▶ When starting patients on medications, what is the most important factor to consider?
- Their level of compliance
- Their diabetes pathology
- Their education level
- d. Their preferences, needs and values






Poll question 2

- ▶ According to the AACE Glycemic Control Algorithm, what is the first step to control hyperglycemia in type 2?
- a. Lifestyle modification
- b. Start insulin
- c. Start metformin
- d. Start 2 meds if their A1c is 7.4%






Poll question 3

- ▶ John is started on Metformin 500mg BID. What of the following is true?
- a. Hold metformin if your blood glucose is below 90 mg/dl.
- b. If you forget to take metformin before the meal, hold the dose.
- c. Take metformin with meals
- d. Always hold metformin if you are sick






Poll Question 4

- ▶ Which of the following is true about sulfonylureas?
- a. Most patients experience some weight loss
- b. 50% of patients have no improvement in BG levels
- c. Do not take with grapefruit juice
- d. Be aware of signs of hypoglycemia






Poll Question 5

- ▶ When goal is to avoid hypoglycemia, which medication class would you recommend?
- Meglitinides
- b. SGLT-2 Inhibitors
- c. Sulfonylureas
- d. Analog insulins






Poll Question 6

- ▶ Alice injects exenatide XR (Bydureon) once a week. Which of the following should she report immediately?
- a. Bump at the injection site
- b. Nausea
- c. Weight loss
- d. Sudden abdominal pain





Poll Question 7

- ▶ For patients on SGLT-2 Inhibitors, a potential side effect is:
- a. Balanitis
- b. Hypertension
- c. Kidney tenderness
- d. Increased uric acid



Diabetes Education

Poll Question 8

- ▶ George type 2, is losing weight and thirsty with an A1c of 10.3%. Using AACE guidelines, what is appropriate action?
- Evaluate lifestyle changes for 3 months
- Start insulin therapy
- Start metformin immediately
- Start metformin plus another agent



Diabetes Agents Considerations

- ▶ Diabetes medications can be used as monotherapy, in combo or with insulin
- ▶ Combining agents from different classes has additive effect
- ▶ Most reduce A1c 0.5 2.0%
- ▶ Not to be used during preconception, pregnancy or when breastfeeding





Patient Centered Approach

- "...providing care that is respectful of and responsive to individual patient preferences, needs, and values ensuring that patient values guide all clinical decisions."
- Gauge patient's preferred level of involvement.
- Explore, where possible, therapeutic choices.
- Utilize decision aids.
- Shared decision making final decisions re: lifestyle choices ultimately lie with the patient.

ADA-EASD Position Statement: Management of Hyperglycemia in T2DM

Diabetes Care 2012;35:1364-1379 Diabetologia 2012;55:1577-1596



Considerations

- ▶ Cost
- ▶ Hypoglycemia
- ▶ Age
- ▶ Weight
- ▶ Comorbidities
 - ▶ Kidney disease
 - ▶ Heart disease CHF, CAD
 - Liver dysfunction

ADA-EASD Position Statement: Management of

Diabetes Care 2012;35:1364-1379 Diabetologia 2012;55:1577-1596





When goal is to minimize cost

- ▶ Go generic. Metformin and Sulfonylureas
- ▶ Walmart offers 3 month supply of following meds for ~ \$10
 - ▶ Metformin and Metformin XR
 - ▶ Glipizide, Glyburide, Glimepiride
- ▶ Other generics include
 - Actos and Avandia
 - Acarbose
 - ▶ Can still cost up to \$100 a month
- ▶ Meds on a Budget Article





Resources for Medications

- ▶ Partnership for Prescription Assistance
 - www.pparx.org
- ▶ NeedyMeds.org
- www.rxassist.org







Diabetes Education

Action/Classes of Type 2 Meds

1. Suppressor Biguanide - Metformin

2. Squirter Sulfonylureas

Meglitinides

3. Satiators **AmylinoMimetics**

> **Incretin Mimetics DPP-4 Inhibitors**


4. Sensitizer Thiazolidinediones (TZD)


5. Glucoretics **SGLT2 Inhibitors**

Dopamine Receptor Agonists 6.Circadian Switchers

Alpha-glucosidase inhibitors 7. Slower







Ideal Diabetes Med -



- ▶ No hypoglycemia
- ▶ No weight gain
- ▶ Affordable
- ▶ Lowers CV risk
- ▶ Most people can tolerate /use?





Biguanides – Suppressor Metformin (Glucophage[®])

- ▶ Action: suppresses release of glycogen from the liver
- ▶ Who?
 - ▶ Fasting hyperglycemia
 - ▶ Dysmetabolic Syndrome
 - ▶ For pediatrics starting age 10
 - ▶ (XR age 17)



Glycogen Stopper and

GLP Enhancer?





Biguanides - Metformin

- ▶ Action: decrease hepatic glucose (glycogen)
- Names:
 - Metformin (Glucophage)
 - ▶ Starting dose: 500 BID, max 2500mg daily
 - Metformin extended release (3 different versions)
 - ▶ Starting dose 500mg at dinner, max dose 2000 to 2500 mg daily
 - Efficacy:
 - ▶ Decrease fasting plasma glucose 60-70 mg/dl
 - ▶ Reduce A1C 1.0-2.0%



Biguanides - Metformin

- Benefits
 - ▶ Decrease LDL cholesterol and triglycerides
 - ▶ No weight gain, possible modest weight loss
 - ▶ Cancer protective?
- Concerns
 - ▶ Diarrhea and abdominal discomfort Use XR
 - ▶ Lactic acidosis if improperly prescribed
 - ▶ Watch for B12 deficiency
 - ▶ Hold prior to IV contrast dye studies and use caution during acute illness. Resume when kidney function adequate





Considerations

Biguanide - Metformin (Glucophage[®])

- ▶ Contraindications due to lactic acidosis:
 - ▶ creatinine >1.4 females, >1.5 males
 - ▶ liver disease
 - alcohol abuse
 - over 80 years old
 - ▶ risk of acidosis
 - during IV dye study
 - ▶ CHF requiring meds







Metformin – How does it rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- ▶ Lowers CV risk?
- ▶ Can most tolerate /use?





Sulfonylureas -

- ▶ Action: tells pancreas to squirt insulin all day
- ▶ Who?
 - ▶ Lean type 2







Sulfonylureas - Squirts

- ▶ Action: Increase endogenous insulin secretion
- ▶ Efficacy:
 - ▶ Decrease FPG 60-70 mg/dl
 - ▶ Reduce A1C by 1.0-2.0%
- ▶ Secondary failures: 5-10% shortly after initial response, many more later
 - ▶ Usually after 5 or more years of therapy due to natural history of DM 2







Sulfonylureas: 2nd Generation

Generic	Trade	Duration
▶ Glyburide	Diabeta, Micronase, most likely to cause hypo – last choice	12-24 hrs
▶ Glipizide*	Glucotrol, Glucotrol XI	12-24 hrs
▶ Glimepiride	Amaryl	16-24 hrs





Sulfonylureas

- **▶** Other Effects
 - ▶ Hypoglycemia
 - ▶ Weight gain
 - ▶ Cleared by kidney, use caution for pts with kidney problems
 - ▶ Generally the least expensive class of medication
 - ▶ Amaryl safest for those with CV Disease





Indication for "Fast Acting" Insulin Secretagogues- Meglitinides

- ▶ Action: tells pancreas to squirt insulin with meals
- ▶ Who?
 - ▶ Targets post-prandial hyperglycemia





Meglitinides - Squirts

- ▶ Action: stimulate insulin secretion (rapid and short duration) when glucose present
- ▶ Names:
 - repaglinide (Prandin)
 - ▶ **Dosing**: 0.5 to 4 mg a.c. Max dose 16mg
 - ▶ Metabolized by liver and mostly excreted in feces (some renally).
 - nateglinide (Starlix)
 - ▶ Dosing: 120 mg tid with meals
 - ▶ Metabolized by liver, excreted by kidney
- ▶ Efficacy:
 - Decreases peak postprandial glucose
 - ▶ Decreases plasma glucose 60-70 mg/dl
 - ▶ Reduce A1C 1.0-2.0%





Meglitinides

- ▶ Other Effects
 - ▶ Hypoglycemia (less than with sulfonylureas if patient has a variable eating schedule)
 - ▶ Minimal weight gain
 - ▶ No significant effect on plasma lipid levels
 - > Safe at higher levels of serum Cr than sulfonylureas





Diabetes Education

Squirters – How does they rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- Lowers CV risk?
- ▶ Can most tolerate /use?



What questions?

▶ 72 yr old, thin, lives alone, A1c 7.3%. History of MI, stroke. DM for 12 yrs, "diet controlled". Limited income. Creat 1.4.





Older Adults - Considerations



- Reduced life expectancy
- Higher CVD burden
- Reduced GFR
- At risk for adverse events from polypharmacy
- More likely to be compromised from hypoglycemia



√ Less ambitious targets

√A1c <7.5-8.0%

Focus on drug safety

Diabetes Care 2012;35:1364-1379 Diabetologia 2012;55:1577-1596



When goal is to avoid Hypoglycemia

- ▶ Avoid sulfonylureas
- Careful insulin dosing
- ▶ May need to up adjust glucose goals
- ▶ Monitor kidney function
- ▶ Reinforce for patients on insulin to "TIE"
 - ▶ Test
 - ▶ Inject
 - ▶ Eat





Diabetes Education

DPP-4 Inhibitors — "Incretin Enhancers"

Januvia (sitagliptin) – Tradjenta (linagliptin) Onglyza (saxagliptin) Nesina (alogliptin)

Action:

- ▶ Increase insulin release w/ meals
- Suppress glucagon
- ▶ **Dosing**: Januvia 100mg a day

Onglyza – up to 5mg a day Tradjenta – 5mg a day

Nesina – up to 25 mg a day

▶ Efficacy: Decreases A1c by 0.6 -0.8%

▶ Indication: For type 2s



DPP-4 Inhibitors - "Incretin Enhancers"

Januvia (sitagliptin) – Tradjenta (linagliptin) Onglyza (saxagliptin) Nesina (alogliptin)

- ▶ Januvia, Onglyza eliminated via kidney, lower dose needed
- ▶ Do not cause wt gain or hypoglycemia
- ▶ Side effects headache, runny nose, sore throat - watch for pancreatitis
- ▶ Cost \$100 \$150 mo





DPP-IV Inhibitors – How do they rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- ▶ Lowers CV risk?
- ▶ Can most tolerate /use?





If on Metformin and Sulfonylurea – A1c 8.4 - Pt struggling with weight







When goal is to avoid weight gain


- ▶ These meds are weight neutral
 - ▶ Metformin
 - ▶ DPP-IV Janvia, Onglyza, Tradjenta, Nesina
 - Acarbose




- ▶ These meds associated with wt loss
 - ▶ GLP-1 agonists (Byetta, Bydureon, Victoza, Tanzeum)
 - ▶ SGLT-2 Inhibitors (Canagliflozin, Dapagliflozin)
 - Symlin (Pramlintide)









Weight Considerations



- Majority of T2DM patients overweight / obese
- Intensive lifestyle program
- Metformin
- **GLP-1** receptor agonists
- ? Bariatric surgery
- Consider LADA in lean patients

Diabetes Care 2012;35:1364-1379 Diabetologia 2012;55:1577-1596

ADA-EASD Position Statement: Management of Hyperglycemia in T2DM



Incretin Mimetics

Exenatide (Byetta), Exenatide XR (Bydureon)

Action:

- ▶ Insulin release in response to meal
- Slows gastric emptying
- Causes Satiety
- Protects Beta Cells

Exenatide Dosing:

- ▶ 5-10 mcg before break, dinner
- ▶ Long acting version 1x week (available in pens in 2015)
- ▶ Efficacy: Decreases A1c by 0.7%, wt by 3lbs
- ▶ Indication: For type 2s only mono or in combo



Incretin Mimetics - GLP-1 Analog Liraglutide (Victoza)

Liraglutide Dosing: 1x daily, time not critical

- 0.6 x 1 week if tolerated (nausea), go to >
- 1.2 x 1 week if tolerated go to >
- 1.8 mg daily
- ▶ Efficacy: lowers; A1c by 1%, body wt by ~ 2.5kg
- ▶ Indication: Monotherapy or in combo . Type 2 only
- ▶ Other: In pen, with preset dosing
- ▶ Black box—thyroid tumor warning (avoid if family hx, notify MD of hoarseness, lump).





Incretin Mimetics –

Exenatide XR - Bydureon


- ▶ Once a Week Dosing: 2mg
- ▶ Efficacy: Decreases A1c by 1.6%, wt by ~6lbs
- ▶ Indication: For type 2s only
- ▶ Other: Pt will need to mix powdered form and inject
 - Pen in future


▶ Caution:

- not indicated for those with history of medullary thyroid
- pancreatitis warning









For all the Previous GLP-1 Agonists

- Pancreatitis Warning
 - Please tell all patients to report signs right away and discontinue meds
 - · Signs include:
 - · Sudden abdominal pain, nausea and vomiting







Incretin Mimetics – How do they rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- ▶ Lowers CV risk?
- ▶ Can most tolerate /use?





What questions?

- ▶ 69 year old male, BMI 25, on Metformin 1000mg BID and Exenatide 10mcg before breakfast and dinner.
- ▶ A1c 8.1%. Creat 1.2
- ▶ Pt is overweight, 11 yr history of diabetes







SGLT2 Inhibitors- "Glucoretics"

▶ **Action**: "Glucoretic" decreases renal reabsorption in the proximal tubule of the kidneys (reset renal threshold and increase glucosuria)

Names:

- Canagliflozin (Invokana)
- ▶ Dosing: 100 300 mg once daily ac first meal If eGFR 45-60: do not exceed 100mg a day
 - ▶ If eGFR <45, do not use

- Empagliflozin Jardiance 10 - 25 mg daily
- If GFR < 60, don't use

- Dapagliflozin (Farxiga)
- ▶ Dosing: 5 10 mg once daily ac first meal
 - ▶ If eGFR <60, do not use
 - ▶ Don't use if pt has bladder cancer and report blood in urine

Efficacy:

- ▶ Weight loss of 1-3 lbs
- Reduce A1C ~0.7-1.5%





Considerations



- May temporarily lower GFR
- Monitor B/P, K+ & renal function.
- Side effects: hypotension, UTI, increased urination, genital yeast infections.
- Other benefits?
 - Reverses glucoses toxicity by increasing GLUT4 transport in muscle
 - Increase liver sensitivity to insulin and decreases gluconeogenesis.





SGLT2 Inhibitors- How do they rate?

Question	Answer
▶ Cause hypoglycemia?	No
▶ Cause weight gain?	No
► Affordable?	No
▶ Lowers CV risk?	No
• Can most tolerate /use?	Yes?



Indications for Insulin Sensitizers

Rosiglitazone (Avandia), Pioglitazone (Actos)

▶ **Action**: decrease insulin resistance by making muscle and adipose cells more sensitive to insulin. Decrease free fatty acids

Names:

- pioglitazone (Actos) bladder cancer warning
 - Dosing: 15-45 mg daily
- rosiglitazone (Avandia) restriction relaxed
 - ▶ Dosing: 4-8 mg daily

Efficacy/ Considerations

- ▶ Reduce A1C ~0.5-1.0%
- ▶ 6 weeks for maximum effect
- ▶ \$100 a month
- Can cause fluid retention, not indicated w/ CHF





TZDs – How do they rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- ▶ Lowers CV risk?
- ▶ Can most tolerate /use?





Indications for Glucosidase Inhibitors Acarbose (Precose¹), Miglitol (Glyset¹)

Action: Slower

- ▶ Target post-prandial blood glucose
- ▶ Minimal systemic absorption







Alpha-glucosidase Inhibitors

- Action: blocks enzymes that digest starches in the small intestine
- Name: acarbose (Precose)
 - ▶ Dosing: 75-300mg based on weight
- ▶ Efficacy
 - ▶ Decrease postprandial glucose 40-50 mg/dl
 - ▶ Decrease A1C 0.5-1.0%
- Other Effects
 - ▶ Flatulence or abdominal discomfort
 - ▶ Contraindicated in patients with inflammatory bowel disease or cirrhosis
- Special Consideration
 - ▶ In case of hypoglycemia, treat with glucose tabs or milk
 - (other starches are blocked by medication))





Acarbose- How does it rate?

Question

Answer

- ▶ Cause hypoglycemia?
- ▶ Cause weight gain?
- ▶ Affordable?
- Lowers CV risk?
- ▶ Can most tolerate /use?






Critical Points

- ▶ Individualize Glycemic targets & BG-lowering
- ▶ Diet, exercise, & education: foundation T2DM therapy
- ▶ Metformin = optimal 1st-line drug.
- ▶ After metformin, data limited. Combo therapy reasonable
- ▶ Ultimately, many T2 patients will require insulin therapy
- ▶ All treatment decisions should be made in conjunction with the patient (focus on preferences, needs & values.)
- CV risk reduction a major focus of therapy.

ADA-EASD Position Statement: Management of Hyperglycemia in T2DM

Diabetes Care 2012;35:1364-1379 Diabetologia 2012;55:1577-1596





Self Sudy - List the Treatment Options

- 35 yr old, BMI 28, creat 0.8, A1c 6.7% Sit 1: Wants to try lifestyle changes before meds Sit 2: Started on Januvia, can't afford it. What alt med?
- ▶ 72 yr old, thin, lives alone, A1c 7.3%. History of MI, stroke. On glyburide 10mg a day and beta blocker. Creat 1.4.
- ▶ 69 year old male, BMI 25, on Metformin 1000mg BID. AM glucose 120s, A1c 8.1%. Creat 1.3
- ▶ 64 yr old on daily; amaryl 4mg, Januvia 100mg, Avandia® 4 mg. A1c 9.2%. Pt c/o of 12 lb wt gain over past month. Creat 1.2, LDL 138
- Pt on Exenatide 10mcg BID, c/o of sudden abd pain.



